Webster K. Cavenee

Webster K. Cavenee (born September 12, 1951 ) is an American molecular geneticist and cancer researcher .

Live and act

Cavenee earned a BA in Biology from Kansas State University in 1973 and a Ph.D. in 1977 with Induction of hela cell 3-hydroxy-3-methylglutaryl coenzyme a reductase by glucocorticoids from the University of Kansas. in microbiology . As a postdoctoral fellow , he worked at the Jackson Laboratory and the Massachusetts Institute of Technology before joining the Howard Hughes Medical Institute at the University of Utah in 1981 . In 1983 he received a first professorship in microbiology and molecular genetics at the University of Cincinnati . In 1986 he moved to the Ludwig Institute for Cancer Research at McGill University , where he held professorships in internal medicine , neurology , pathology and human genetics . Since 1991 Cavenee has been Professor of Internal Medicine at the University of California, San Diego , and from 1991 to 2015 he was founding director of the Ludwig Institute for Cancer Research there . His successor was Richard D. Kolodner .

Cavenee is best known for the discovery that there are tumor suppressor genes , which confirms the Knudson hypothesis ("two-hit hypothesis"). Mutations in tumor suppressor genes are considered to be the (co-) cause of around half of all cancers and the target of new cancer therapies. The evidence that the loss of heterozygosity can lead to cancer development goes back to him , for the first time using the example of retinoblastoma . Later work dealt with the glioblastoma and its genetic causes, including the mutation of the EGF receptor , which thereby became accessible for targeted cancer therapy . Since 2015, Cavenee has been the coordinator of an international research alliance of the Ludwig Institute for the development of clinical test procedures for the therapy of glioblastoma.

Cavenee is the author of more than 300 scientific publications .

Awards (selection)

• 1990 Charles S. Mott Prize from the General Motors Cancer Research Foundation
• 1997 member of the National Academy of Sciences
• 1997 member of the American Academy of Microbiology
• 1998 President of the American Association for Cancer Research
• 2004 Member of the National Foundation for Cancer Research
• 2007 Szent-Györgyi Prize of the National Foundation for Cancer Research
• 2007 Member of the Institute of Medicine (now National Academy of Medicine )
• 2008 Fellow of the American Association for the Advancement of Science
• 2012 member of the German Academy of Sciences Leopoldina
• 2013 Fellow of the American Association for Cancer Research

Fonts (selection)

• Recessive oncogenes and tumor suppression , 1989
• Genetics and cancer , 1995
• The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. In: Acta neuropathologica May 9, 2016: pp. 1-18

Web links

• Webster Cavenee at the Ludwig Institute for Cancer Research (ludwigcancerresearch.org)
• Webster K. Cavenee, Ph.D. at the National Foundation for Cancer Research (nfcr.org)
• Live data, publications and Academic pedigree of Webster Cavenee at academictree.org, accessed on 17 July 2018th

Individual evidence

1. ^ Charles S. Mott Prize (1990–2002) ( Memento of March 14, 2007 in the Internet Archive )
2. ↑ Webster Cavenee. In: nasonline.org. Retrieved July 17, 2018 . 
3. ^ Presidents of the AACR. In: aacr.org. July 17, 2018, accessed on July 17, 2018 . 
4. ↑ National Foundation For Cancer Research called UCSD's Webster Cavenee NFCR Fellow. In: eurekalert.org. March 23, 2004, accessed July 17, 2018 . 
5. ↑ 2007 Szent-Györgyi Prize Prize: Webster K. Cavenee, Ph.D. In: nfcr.org. July 11, 2018, accessed on July 17, 2018 . 
6. ↑ Cavenee, Webster. In: aaas.org. February 18, 2017, accessed July 17, 2018 . 
7. ↑ member entry of Webster K. Cavenee at the German Academy of Sciences Leopoldina , accessed on 17 July 2018th
8. ↑ Webster K. Cavenee, PhD. In: aacr.org. July 17, 2018, accessed on July 17, 2018 .